A study investigating rivaroxaban to assess various outcomes of cancer patients with blood clots who are treated with an anticoagulant to better understand the treatment of VTE and the prevention of recurrent events in this patient population

Trial Profile

A study investigating rivaroxaban to assess various outcomes of cancer patients with blood clots who are treated with an anticoagulant to better understand the treatment of VTE and the prevention of recurrent events in this patient population

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2015

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Cancer; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CALLISTO
  • Most Recent Events

    • 07 Dec 2015 According to a Janssen Pharmaceuticals media release, results from first 200 patients were presented at the 2015 American Society of Hematology (ASH) Annual Meeting.
    • 07 Dec 2015 Results from first 200 patients were published in a Janssen Pharmaceuticals media release.
    • 07 Dec 2015 Status changed from planning to recruiting, according to a Janssen Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top